Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pharmacol ; 84(1): 147-57, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23658008

ABSTRACT

Low molecular weight fucoidan (LMWF) is widely used to treat metabolic disorders, but its physiologic effects have not been well determined. In the present study, we investigated the metabolic effects of LMWF in obese diabetic mice (leptin receptor-deficient db/db mice) and the underlying molecular mechanisms involved in endoplasmic reticulum (ER) stress-responsive L6 myotubes. The effect of LMWF-mediated AMP-activated protein kinase (AMPK) activation on insulin resistance via regulation of the ER stress-dependent pathway was examined in vitro and in vivo. In db/db mice, LMWF markedly reduced serum glucose, triglyceride, cholesterol, and low-density lipoprotein levels, and gradually reduced body weights by reducing lipid parameters. Furthermore, it effectively ameliorated glucose homeostasis by elevating glucose tolerance. In addition, the phosphorylation levels of AMPK and Akt were markedly reduced by ER stressor, and subsequently, glucose uptake and fatty acid oxidation were also reduced. However, these adverse effects of ER stress were significantly ameliorated by LMWF. Finally, in L6 myotubes, LMWF markedly reduced the ER stress-induced upregulation of the mammalian target of rapamycin-p70S61 kinase network and subsequently improved the action of insulin via AMPK stimulation. Our findings suggest that AMPK activation by LMWF could prevent metabolic diseases by controlling the ER stress-dependent pathway and that this beneficial effect of LMWF provides a potential therapeutic strategy for ameliorating ER stress-mediated metabolic dysfunctions.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Endoplasmic Reticulum Stress/drug effects , Homeostasis/drug effects , Insulin Resistance/physiology , Lipid Metabolism/drug effects , Muscle Fibers, Skeletal/metabolism , Polysaccharides/pharmacology , Animals , Body Weight , Cholesterol/blood , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Glucose/metabolism , Lipids , Lipoproteins, LDL/blood , Male , Mice , Mice, Inbred C57BL , Mice, Obese , Molecular Weight , Muscle Fibers, Skeletal/drug effects , Phosphorylation/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Triglycerides/blood
2.
J Microbiol ; 50(3): 380-5, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22752900

ABSTRACT

Plant growth promoting rhizobacteria Ochrobactrum lupini KUDC1013 and Novosphingobium pentaromativorans KUDC1065 isolated from Dokdo Island, S. Korea are capable of eliciting induced systemic resistance (ISR) in pepper against bacterial spot disease. The present study aimed to determine whether plant growth-promoting rhizobacteria (PGPR) strains including strain KUDC1013, strain KUDC1065, and Paenibacillus polymyxa E681 either singly or in combinations were evaluated to have the capacity for potential biological control and plant growth promotion effect in the field trials. Under greenhouse conditions, the induced systemic resistance (ISR) effect of treatment with strains KUDC1013 and KUDC1065 differed according to pepper growth stages. Drenching of 3-week-old pepper seedlings with the KUDC-1013 strain significantly reduced the disease symptoms. In contrast, treatment with the KUDC1065 strain significantly protected 5-week-old pepper seedlings. Under field conditions, peppers treated with PGPR mixtures containing E681 and KUDC1013, either in a two-way combination, were showed greater effect on plant growth than those treated with an individual treatment. Collectively, the application of mixtures of PGPR strains on pepper might be considered as a potential biological control under greenhouse and field conditions.


Subject(s)
Capsicum/growth & development , Capsicum/microbiology , Ochrobactrum/physiology , Paenibacillus/physiology , Sphingomonadaceae/physiology , Antibiosis , Pest Control, Biological , Republic of Korea
3.
Biochem Biophys Res Commun ; 418(2): 402-7, 2012 Feb 10.
Article in English | MEDLINE | ID: mdl-22281494

ABSTRACT

This study was designed to evaluate the role of mammalian target of rapamycin (mTOR)/p70S61 kinase (S6K1) pathways in ER stress-induced insulin resistance in L6 myotubes. Pretreatment with 5µg/ml of tunicamycin or 600nM thapsigargin for 3h decreased insulin-mediated tyrosine phosphorylation of IRS-1 and glucose uptake, and increased the level of mTOR/S6K1 phosphorylation in L6 myotubes. However, the inhibition of mTOR activity by rapamycin (inhibitor of several intracellular pathways including S6K1 pathways) reversed the ER stress-reduced tyrosine phosphorylation of IRS-1 and glucose uptake. Furthermore, pretreatment of cells with rapamycin decreased ER stress-induced phosphorylation of mTOR and S6K1. Interestingly, inhibition of mTOR by rapamycin did not affect ER stress markers such as PERK and JNK activity under the ER stress condition. Similar results were obtained with or without pretreatment with tunicamycin in the absence or presence of S6K1 RNAi. Moreover, S6K1 RNAi-mediated knockdown preserved insulin-stimulated Akt phosphorylation and glucose uptake in ER-stressed L6 myotubes, which was blocked by the phosphatidylinositol 3-kinase inhibitor wortmannin. Taken together, these results suggest that rapamycin improved ER stress-induced insulin resistance via inhibition of mTOR/S6K1 hyperphosphorylation in L6 myotubes.


Subject(s)
Insulin Resistance , Insulin/pharmacology , Ribosomal Protein S6 Kinases/antagonists & inhibitors , Sirolimus/pharmacology , TOR Serine-Threonine Kinases/antagonists & inhibitors , Animals , Cell Line , Endoplasmic Reticulum Stress/drug effects , Gene Knockdown Techniques , Glucose/metabolism , Insulin Receptor Substrate Proteins/metabolism , Muscle Fibers, Skeletal/drug effects , Muscle Fibers, Skeletal/enzymology , Phosphorylation/drug effects , Rats , Ribosomal Protein S6 Kinases/genetics , Tyrosine/metabolism
4.
Biochem Biophys Res Commun ; 377(4): 1253-8, 2008 Dec 26.
Article in English | MEDLINE | ID: mdl-18992226

ABSTRACT

AMP-activated protein kinase (AMPK) is an energy-sensing enzyme that has been implicated as a key factor for controlling intracellular lipids and glucose metabolism. Beta-sitosterol, a plant sterol known to prevent cardiovascular disease was identified from Schizonepeta tenuifolia to an AMPK activator. In L6 myotube cells, beta-sitosterol significantly increased phosphorylation of the AMPKalpha subunit and acetyl-CoA carboxylase (ACC) with stimulating glucose uptake. In contrast, beta-sitosterol treatment reduced intracellular levels of triglycerides and cholesterol in L6 cells. These effects were all reversed by pretreatment with AMPK inhibitor Compound C or LKB1 destabilizer radicicol. Similarly, beta-sitosterol-induced phosphorylation of AMPK and ACC was not increased in HeLa cells lacking LKB1. These results together suggest that beta-sitosterol-mediated enhancement of glucose uptake and reduction of triglycerides and cholesterol in L6 cells is predominantly accomplished by LKB1-mediated AMPK activation. Our findings further reveal a molecular mechanism underlying the beneficial effects of beta-sitosterol on glucose and lipid metabolism.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Glucose/metabolism , Hypolipidemic Agents/pharmacology , Lipid Metabolism/drug effects , Muscle Fibers, Skeletal/drug effects , Sitosterols/pharmacology , AMP-Activated Protein Kinase Kinases , Animals , Cell Line , Cholesterol/metabolism , Enzyme Activation , Glucose Transporter Type 4/metabolism , Humans , Muscle Fibers, Skeletal/metabolism , Protein Serine-Threonine Kinases/metabolism , Protein Transport/drug effects , Rats , Signal Transduction/drug effects , Triglycerides/metabolism
5.
Biochem Biophys Res Commun ; 371(2): 289-93, 2008 Jun 27.
Article in English | MEDLINE | ID: mdl-18435912

ABSTRACT

AMP-activated protein kinase (AMPK) is an energy-sensing enzyme that is implicated as a key factor in controlling whole body homeostasis, including fatty acid oxidation and glucose uptake. We report that a synthetic structural isomer of dihydrocapsiate, isodihydrocapsiate (8-methylnonanoic acid 3-hydroxy-4-methoxy benzyl ester) improves type 2 diabetes by activating AMPK through the LKB1 pathway. In L6 myotube cells, phosphorylation of AMPK and acetyl-CoA carboxylase (ACC) and glucose uptake were significantly increased, whereas these effects were attenuated by an AMPK inhibitor, compound C. In addition, increased phosphorylation of AMPK and ACC by isodihydrocapsiate was significantly reduced by radicicol, an LKB1 destabilizer, suggesting that increased glucose uptake in L6 cells with isodihydrocapsiate treatment is predominantly accomplished by a LKB1-mediated AMPK activation pathway. Oral administration of isodihydrocapsiate to diabetic (db/db) mice reduced blood glucose levels by 40% after a 4-week treatment period. Our results support the development of isodihydrocapsiate as a potential therapeutic agent to target AMPK in type 2 diabetes.


Subject(s)
Blood Glucose/drug effects , Capsaicin/analogs & derivatives , Diabetes Mellitus, Type 2/enzymology , Hypoglycemic Agents/pharmacology , Multienzyme Complexes/metabolism , Protein Serine-Threonine Kinases/metabolism , AMP-Activated Protein Kinases , Acetyl-CoA Carboxylase/metabolism , Animals , Blood Glucose/metabolism , Capsaicin/administration & dosage , Capsaicin/chemistry , Capsaicin/pharmacology , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/chemistry , Mice , Mice, Inbred Strains , Phosphorylation/drug effects , Rats
6.
Plant Cell Rep ; 23(6): 386-90, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15368075

ABSTRACT

A reproducible plant regeneration and an Agrobacterium tumefaciens-mediated genetic transformation protocol were developed for Perilla frutescens (perilla). The largest number of adventitious shoots were induced directly without an intervening callus phase from hypocotyl explants on MS medium supplemented with 3.0 mg/l 6-benzylaminopurine (BA). The effects of preculture and extent of cocultivation were examined by assaying beta-glucuronidase (GUS) activity in explants infected with A. tumefaciens strain EHA105 harboring the plasmid pIG121-Hm. The highest number of GUS-positive explants were obtained from hypocotyl explants cocultured for 3 days with Agrobacterium without precultivation. Transgenic perilla plants were regenerated and selected on MS basal medium supplemented with 3.0 mg/l BA, 125 mg/l kanamycin, and 500 mg/l carbenicillin. The transformants were confirmed by PCR of the neomycin phosphotransferase II gene and genomic Southern hybridization analysis of the hygromycin phosphotransferase gene. The frequency of transformation from hypocotyls was about 1.4%, and the transformants showed normal growth and sexual compatibility by producing progenies.


Subject(s)
Agrobacterium tumefaciens/genetics , Gene Transfer Techniques , Perilla frutescens/genetics , Genetic Vectors , Perilla frutescens/growth & development , Phenotype , Plants, Genetically Modified/growth & development , Seedlings/genetics , Seedlings/growth & development , Transformation, Genetic
7.
Eur J Pharmacol ; 494(1): 1-9, 2004 Jun 21.
Article in English | MEDLINE | ID: mdl-15194445

ABSTRACT

Triptolide (PG490) is a natural, biologically active compound extracted from the Chinese herb Tripterygium wilfordii. It has been shown to possess potent anti-inflammatory and immunosuppressive properties. In Raw 264.7 cells stimulated with lipopolysaccharide (LPS) to mimic inflammation, triptolide inhibits nitric oxide (NO) production in a dose-dependent manner and abrogates inducible nitric oxide synthase (iNOS) gene expression. To investigate the mechanism by which triptolide inhibits murine iNOS gene expression, we examined activation of mitogen-activated protein kinases (MAP kinases) and nuclear factor-kappa B (NF-kappa B) in these cells. Addition of triptolide inhibited phosphorylation of c-Jun NH(2)-terminal kinase (JNK) but not that of extracellular signal-regulated kinase (ERK) or p38 mitogen-activated protein kinase. In addition, triptolide significantly inhibited the DNA binding activity of NF-kappa B. Taken together, these results suggest that triptolide acts to inhibit inflammation through inhibition of NO production and iNOS expression through blockade of NF-kappa B and JNK activation.


Subject(s)
Diterpenes/pharmacology , Down-Regulation/drug effects , JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , Lipopolysaccharides/pharmacology , NF-kappa B/antagonists & inhibitors , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/biosynthesis , Phenanthrenes/pharmacology , Animals , Cell Line , Diterpenes/chemistry , Down-Regulation/physiology , Enzyme Inhibitors/pharmacology , Epoxy Compounds , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Enzymologic/physiology , JNK Mitogen-Activated Protein Kinases/metabolism , Lipopolysaccharides/antagonists & inhibitors , Mice , NF-kappa B/metabolism , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase Type II , Phenanthrenes/chemistry
8.
Carcinogenesis ; 25(10): 1813-20, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15142888

ABSTRACT

Sodium butyrate, a short-chain fatty acid naturally present in the human colon, is able to induce cell cycle arrest, differentiation and apoptosis in various cancer cells. Sodium butyrate is most probably related to the inhibition of deacetylases leading to hyperacetylation of chromatin components such as histones and non-histone proteins and to alterations in gene expression. In this study, we demonstrate for the first time that sodium butyrate selectively up-regulated DR5 but had no effect on the expression of the other TNF-alpha-related apoptosis-inducing ligand (TRAIL) receptor, DR4. Sodium butyrate-induced expression of DR5 involves the putative Sp1 site within the DR5 promoter region. Using a combination of the electrophoretic mobility shift assay and the luciferase reporter assay, we found that a specific Sp1 site (located at -195 bp relative to the transcription start site) is required for sodium butyrate-mediated activation of the DR5 promoter. When HCT116 cells were incubated with sodium butyrate and TRAIL, enhanced TRAIL-mediated apoptosis was observed. The enhanced apoptosis was measured by fluorescent activated cell sorting analysis, DNA fragmentation, poly (ADP-ribose) polymerase cleavage, down-regulation of XIAP and caspase activity. Taken together, the present studies suggest that sodium butyrate may be an effective sensitizer of TRAIL-induced apoptosis.


Subject(s)
Apoptosis/drug effects , Butyrates/pharmacology , Colonic Neoplasms/metabolism , Membrane Glycoproteins/pharmacology , Receptors, Tumor Necrosis Factor/metabolism , Sp1 Transcription Factor/metabolism , Transcription, Genetic/drug effects , Tumor Necrosis Factor-alpha/pharmacology , Apoptosis Regulatory Proteins , Caspases/metabolism , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , Down-Regulation , Electrophoretic Mobility Shift Assay , Enzyme Inhibitors/pharmacology , Histone Deacetylase Inhibitors , Humans , Hydroxamic Acids/pharmacology , Luciferases/metabolism , Poly(ADP-ribose) Polymerases/metabolism , Promoter Regions, Genetic/genetics , Proteins/metabolism , Receptors, TNF-Related Apoptosis-Inducing Ligand , TNF-Related Apoptosis-Inducing Ligand , Tumor Cells, Cultured , Up-Regulation , X-Linked Inhibitor of Apoptosis Protein
9.
Biochem Pharmacol ; 66(9): 1779-86, 2003 Nov 01.
Article in English | MEDLINE | ID: mdl-14563488

ABSTRACT

Daunorubicin (DNR) induces apoptosis in the human myeloid leukemia cells by activation of neutral sphingomyelinease and ceramide production. In the present study, we determined the effect of the antiapoptosis protein Bcl-2 on caspase-3 activation, phospholipase C-gamma 1 (PLC-gamma 1) degradation and cytochrome c release during the DNR-induced apoptosis. Treatment with 3 microM DNR for 12 hr produced morphological features of apoptosis and DNA fragmentation in U937 cells, which was associated with caspase-3 activation and PLC-gamma 1 degradation. Induction of apoptosis was also accompanied by release of cytochrome c, down-regulation of X-linked inhibitor of apoptosis protein (XIAP), and inactivation of Akt, which was blocked by the pan-caspase inhibitor z-VAD-fmk. DNR-induced caspase-3 activation, PLC-gamma 1 degradation and apoptosis were significantly attenuated in Bcl-2 overexpressing U937/Bcl-2 cells. Ectopic expression of Bcl-2 appeared to inhibit DNR-induced apoptosis by interfering with inhibition of XIAP and Akt degradation.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis , Caspases/metabolism , Daunorubicin/pharmacology , Protein Serine-Threonine Kinases , Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Proto-Oncogene Proteins/metabolism , Caspase 3 , Humans , Neoplasm Proteins/metabolism , Proteins/antagonists & inhibitors , Proto-Oncogene Proteins/antagonists & inhibitors , Proto-Oncogene Proteins c-akt , Proto-Oncogene Proteins c-bcl-2/genetics , U937 Cells , X-Linked Inhibitor of Apoptosis Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...